Obesity's Impact on Heart Health
Trial Summary
What is the purpose of this trial?
A multidisciplinary investigation examining the circadian mechanisms regulating cardiovascular (CV) risk in obesity. Specifically, in a valid circadian protocol, the investigators aim to study resting cardiovascular risk markers and the reactivity of circadian rhythms in these risk markers to standardized stressors in obesity. Furthermore, using an ingenious approach, the investigators propose to explore impairment in pre/post synaptic function in the cardiac left ventricle.
Research Team
Jeanne M Link, PhD
Principal Investigator
OHSU Center for Radiochemistry Research
Steven A Shea, PhD
Principal Investigator
Oregon Institute of Occupational Health Sciences
Eligibility Criteria
This trial is for adults aged 25-65 who are not very active and have a body mass index (BMI) between 18.5 to 40, meaning they range from normal weight to obese. It's not open to smokers, those with sleep issues like insomnia or severe sleep apnea, anyone on prescription meds or using drugs of abuse, or people with certain medical conditions including diabetes and high blood pressure.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- 11C-CGP12177 (Radiopharmaceutical)
- 11C-Meta-Hydroxyephedrine (mHED) (Radiopharmaceutical)
- Circadian Study Protocol (Behavioral)
- O15-water (Radiopharmaceutical)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Oregon Health and Science University
Lead Sponsor